Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Antiarrhythmic Drugs Use in Elderly Patients. Vaughan Williams Class III and IV Drugs

https://doi.org/10.20996/1819-6446-2016-12-5-603-609

Full Text:

Abstract

The effectiveness of antiarrhythmic drugs in the elderly is similar to that in younger patients. However data for «the very elderly» are lacking. Elderly patients are more vulnerable to adverse drug reactions (ADRs) because of age-related changes of pharmacokinetics, co-morbidity and drug interactions. Аmioadarone is not considered as the drug of choice in elderly patients because of the high risk of serious ADRs. Other class III drugs should be prescribed to the elderly with great caution under close monitoring of the treatment. Diltiazem and verapamil should not be used in elderly patients with NYHA class III-IV heart failure and should not be combined with β-blockers.

About the Authors

E. A. Ushkalova
People's Friendship University of Russia. Miklukho-Maklaya ul. 6, Moscow, 117198 Russia
Russian Federation

MD, PhD, Professor of Chair of the General and Clinical Pharmacology, People's Friendship University of Russia



S. K. Zyryanov
People's Friendship University of Russia. Miklukho-Maklaya ul. 6, Moscow, 117198 Russia
Russian Federation

MD, PhD, Head of Chair of the General and Clinical Pharmacology, People's Friendship University of Russia



K. E. Zatolochina
People's Friendship University of Russia. Miklukho-Maklaya ul. 6, Moscow, 117198 Russia
Russian Federation

MD, PhD, Teaching Assistant of Chair of the General and Clinical Pharmacology, People's Friendship University of Russia



A. P. Pereverzev
People's Friendship University of Russia. Miklukho-Maklaya ul. 6, Moscow, 117198 Russia
Russian Federation

MD, PhD, Associate Professor of Chair of the General and Clinical Pharmacology, People's Friendship University of Russia



N. A. Chukhareva
Scientific Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov. Academika Oparina ul. 4, Moscow, 117997 Russia
Russian Federation

MD, Junior Researcher, Internal Medicine Department, Scientific Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov



References

1. Sviridenko NY, Bokalov SA, Serdyuk SE, et al. The conditions caused by amiodarone, in practice, the cardiologist and endocrinologist. Lechacshii Vrach 2004; 2: 16-20. In Russian (Свириденко Н.Ю., Бокалов С.А., Сердюк С.Е. и др. Состояния, вызванные приемом амиодарона, в практике кардиолога и эндокринолога. Лечащий Врач 2004; 2: 16-20).

2. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298(11):1312-22.

3. Kawabata M, Hirao K, Hachiya H, et al. Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. J Cardiol 2011;58:108-15.

4. Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Europace 2010;12:1360-420.

5. Vamos M, Hohnloser SH. Amiodarone and dronedarone: An update. Trends Cardiovasc Med 2016 Apr 4. [Epub ahead of print].

6. Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev 2015 Dec 8;(12):CD008093.

7. van Erven L, Schalij MJ. Amiodarone: an effective antiarrhythmic drug with unusual side effects. Heart 2010;96:1593-600.

8. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-34.

9. Kalus JS. Pharmacologic management of atrial fibrillation: established and emerging options. J Manag Care Pharm 2009;15(6 Suppl B):S10-8.

10. Ahmad S. Amiodarone and lipid disorder [letter]. Arch Intern Med 1995; 155: 1912.

11. Pollak PT, Sharma AD, Carruthers SG. Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. Am J Cardiol 1988; 62: 562-5.

12. Zgazarova S, Jedlickova H, Vasku V. Unwanted skin effects of amiodaron. Vnitr Lek 2009;55(10):976-80.

13. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a metaanalysis of randomized controlled trials. Eur Heart J 2009;30:1245-53.

14. Herre J, Sauve M, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation.J Am Coll Cardiol 1989;13:442-9.

15. Le Heuzey JY, De Ferrari GM, Radzik D et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605

16. Ehrlich C, Tsu LV. Updates in antiarrhythmic therapy for atrial fibrillation in geriatric patients. Consult Pharm 2015;30(2):82-91.

17. Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007; 71: 1610-6.

18. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935-41.

19. Beers Criteria Update Expert Panel. American Geriatric Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63(11):2227-46.

20. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008;37(6):673-9.

21. O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44(2):213-8.

22. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36(41):2793-867.

23. Wann LS, Curtis AB, Ellenbogen KA, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013;127(18):1916-26.

24. Karamichalakis N, Letsas KP, Vlachos K, et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag 2015;11:555-62.

25. Deneer VH, van Hemel NM. Is Antiarrhythmic Treatment in the Elderly Different? A Review of the Specific Changes.Drugs Aging 2011;28(8):617-33.

26. Frishman WH, Aronow WS. Pharmacology of Antiarrhythmic Drugs in Elderly Patient. Clin Geriatr Med 2012;28(4):575-615.

27. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26(6):421-38.

28. Kubesova HM, Weber P, Meluzinova H, et al. Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr 2013;125(15-16):425-36.

29. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49: 373-8.

30. Tadros R, Nattel S, Andrade JG. Dronedarone: Basic Pharmacology and Clinical Use. Card Electrophysiol Clin 2016;8(2):453-65.

31. Rochetaing A, Barbe´ C, Kreher P. Beneficial effects of amiodarone and dronedarone (SR33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters assessed during reperfusion in isolated rat hearts. J Cardiovasc Pharmacol 2001;38:500-11.

32. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357(10):987-99.

33. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol 2008;19(11):1220-26.

34. De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf 2012;11(6):1023-45.

35. Food and Drug Administration. FDA Drug Safety Communication: severe liver injury associated with the use of dronedarone (marketed as Multaq). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm. Checked by 12.08.2016.

36. Piccini JP, Hasselblad V, Peterson ED et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089-95.

37. Nattel S. Dronedarone in atrial fibrillation - Jekyll and Hyde? (editorial). N Engl J Med 2011;365:2321.

38. Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110(4):607-13.

39. Connolly SJ, Camm AJ, Halperin JL, et al, for the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.

40. Hohnloser SH, Crijns HJ, van EM, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.

41. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007;41(4):599-605.

42. ElMaghawry M, Farouk M. Dronedarone-digoxin interaction in PALLAS: A foxglove connection? Glob Cardiol Sci Pract 2015;2015:4.

43. The Institute for Safe Medication Practices. QuarterWatch: 2010 Quarter 1. Signals for Acetaminophen, dronedarone and Botulinum Toxin Products. Available at: http://www.ismp.org/quarterwatch/2010Q1.pdf. Checked by 12.08.2016.

44. Food and Drug Administration. Labeling revision: highlights of prescribing information (Multaq). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/ 022425s002lbl.pdf. Checked by 12.08.2016.

45. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012;125:381-9.

46. Korantzopoulos P1, Letsas KP, Kotsia A, et al. Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients. World J Cardiol 2013;5(7):242-6.

47. Reiffel JA. Ibutilide as a Torsade de Pointes Stress Test. J Am Coll Cardiol 2016;67(23):2806.

48. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91(6A):15D-26D.

49. Torp-Pedersen C, Møller M, Block-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341(12):857-65.

50. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation 2006;114(7):e257-354.

51. Lang ES, Browning K. Ventricular tachyarrhythmias (out-of-hospital cardiac arrests). BMJ Clin Evid 2010;2010.

52. Wauters M, Elseviers M, Vaes B, et al. Mortality, hospitalisation, institutionalisation in community-dwelling oldest old: The impact of medication. Arch Gerontol Geriatr 2016;65:9-16.

53. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64:369-37.

54. Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76:281-292.

55. Wang YC, Hsieh TC, Chou CL, et al. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Medicine (Baltimore) 2016;95(2)2487.

56. Lewin JJJ3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002; 36:1546-9.


For citation:


Ushkalova E.A., Zyryanov S.K., Zatolochina K.E., Pereverzev A.P., Chukhareva N.A. Antiarrhythmic Drugs Use in Elderly Patients. Vaughan Williams Class III and IV Drugs. Rational Pharmacotherapy in Cardiology. 2016;12(5):603-609. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-5-603-609

Views: 616


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)